IL281600B2 - Cancer treatment methods - Google Patents

Cancer treatment methods

Info

Publication number
IL281600B2
IL281600B2 IL281600A IL28160021A IL281600B2 IL 281600 B2 IL281600 B2 IL 281600B2 IL 281600 A IL281600 A IL 281600A IL 28160021 A IL28160021 A IL 28160021A IL 281600 B2 IL281600 B2 IL 281600B2
Authority
IL
Israel
Prior art keywords
compound
formula
cancer
effective amount
therapeutically effective
Prior art date
Application number
IL281600A
Other languages
English (en)
Hebrew (he)
Other versions
IL281600A (en
IL281600B1 (en
Original Assignee
Endocyte Inc
Mike Sathekge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc, Mike Sathekge filed Critical Endocyte Inc
Publication of IL281600A publication Critical patent/IL281600A/en
Publication of IL281600B1 publication Critical patent/IL281600B1/en
Publication of IL281600B2 publication Critical patent/IL281600B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL281600A 2018-09-21 2019-09-20 Cancer treatment methods IL281600B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862734649P 2018-09-21 2018-09-21
PCT/US2019/052161 WO2020061458A1 (en) 2018-09-21 2019-09-20 Methods of treating cancer

Publications (3)

Publication Number Publication Date
IL281600A IL281600A (en) 2021-05-31
IL281600B1 IL281600B1 (en) 2025-11-01
IL281600B2 true IL281600B2 (en) 2026-03-01

Family

ID=69887889

Family Applications (2)

Application Number Title Priority Date Filing Date
IL281600A IL281600B2 (en) 2018-09-21 2019-09-20 Cancer treatment methods
IL323981A IL323981A (en) 2018-09-21 2025-10-15 Methods of treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL323981A IL323981A (en) 2018-09-21 2025-10-15 Methods of treating cancer

Country Status (9)

Country Link
US (1) US20220125957A1 (enExample)
EP (1) EP3852816A4 (enExample)
JP (2) JP2022501441A (enExample)
KR (1) KR20210095620A (enExample)
CN (4) CN121338051A (enExample)
AU (2) AU2019345320B2 (enExample)
CA (1) CA3112806A1 (enExample)
IL (2) IL281600B2 (enExample)
WO (1) WO2020061458A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
JP2023539990A (ja) 2020-07-13 2023-09-21 ポイント バイオファーマ インコーポレイテッド 放射性薬剤および方法
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160228587A1 (en) * 2013-10-18 2016-08-11 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
EP3400229B1 (en) * 2016-01-10 2024-03-06 Provincial Health Services Authority 18/19f-labelled compounds which target the prostate specific membrane antigen
DK3498308T3 (da) * 2017-12-13 2025-01-02 Sciencons AS Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160228587A1 (en) * 2013-10-18 2016-08-11 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRATOCHWIL CLEMENS ET AL,, PSMA-TARGETED RADIONUCLIDE THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH 177 LU-LABELED PSMA-617, 16 March 2016 (2016-03-16) *
SATHEKGE MIKE ET AL,, 225AC-PSMA-617 IN CHEMOTHERAPY-NAIVE PATIENTS WITH ADVANCED PROSTATE CANCER: A PILOT STUDY, 19 September 2018 (2018-09-19) *

Also Published As

Publication number Publication date
IL323981A (en) 2025-12-01
CN121338051A (zh) 2026-01-16
CN121154858A (zh) 2025-12-19
EP3852816A1 (en) 2021-07-28
CN113164631A (zh) 2021-07-23
IL281600A (en) 2021-05-31
KR20210095620A (ko) 2021-08-02
AU2026201845A1 (en) 2026-04-02
EP3852816A4 (en) 2022-07-13
CA3112806A1 (en) 2020-03-26
WO2020061458A1 (en) 2020-03-26
US20220125957A1 (en) 2022-04-28
AU2019345320B2 (en) 2025-12-11
JP2022501441A (ja) 2022-01-06
IL281600B1 (en) 2025-11-01
JP2024178159A (ja) 2024-12-24
CN121130116A (zh) 2025-12-16
AU2019345320A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
IL260199B (en) Cancer treatment methods
IL255189A0 (en) Cancer treatment methods
IL277981A (en) Cancer treatment methods
IL283337A (en) Methods for treating whsc1-overexpressing cancers by inhibiting setd2
IL262342A (en) Cancer treatment methods
PT3490560T (pt) Niraparib para utilização num método de tratamento de cancro da próstata
ZA201808258B (en) Methods of treating pancreatic cancer
SG11202011117VA (en) Treatment of cancer
SG11202010793UA (en) Methods of treating cancer
IL286297A (en) Minimal residual cancer treatment methods
ZA201908539B (en) Method of treatment of cancer
SG11202107017TA (en) Methods of treating cancer
SG11202000839TA (en) Methods of treating cancer by inhibiting setd2
IL289811A (en) A method for treating cancer
EP3487999A4 (en) METHODS OF TREATING CANCER
IL282948B2 (en) Cancer treatment preparations and methods
IL279591A (en) Cancer treatment methods using combination therapy
GB201717945D0 (en) Method for treatment of cancer
GB201820098D0 (en) Methods of cancer treatment
SG11202005163PA (en) Methods of treating cancer
IL269123A (en) Methods of treating cancer
IL274748A (en) Improved cancer treatment
GB201820975D0 (en) Methods of cancer treatment
GB201918815D0 (en) Treatment of cancer